Sort
15,273 grants matching “antimicrobial resistance”
Deimmunized Griffithsin Microbicide
$299,275Chris Bailey-Kellogg · Stealth Biologics, Llc · R44 · FY2020 · AI
Development of a predictive moderate throughput assay to screen novel Designer Proline-rich antimicrobial peptide Chaperone protein inhibitors (DPCs) against multi-drug resistant pathogen
$299,248Carl Neil Kraus · Arrevus, Inc. · R41 · FY2019 · AI
RAPID AFFORDABLE TB DRUG SUSCEPTIBILITY TESTING
$299,229Howard M. Shapiro · Howard M. Shapiro, Md, P.C. · R43 · FY2008 · AI
Infectious Disease Training in Clinical Investigation
$299,185James R Johnson · University Of Minnesota · T32 · FY2007 · AI
Rapid, equitable, lateral flow-based antibiotic susceptibility testing for urinary tract infections
$299,170Emily S Melzer · Latde Diagnostics Corp. · R43 · FY2024 · AI
Texas Medical Center Training Program in Antimicrobial Resistance
$299,169Anthony Richard Flores · University Of Texas Hlth Sci Ctr Houston · T32 · FY2021 · AI
Harnessing mRNA Vaccine Technology for Precision Antimicrobial Delivery
$299,163Ivan Liachko · Phase Genomics, Inc. · R43 · FY2025 · AI
2-adamantanamine Based Therapeutic for Recurrent Oropharyngeal Candidiasis
$299,157Thomas A Dahl · Arietis · R43 · FY2011 · DE
Ceragenin-based antimicrobial coating to tackle hemodialysis catheter-related infections.
$299,155Glenn Brunner · N8 Medical, Inc. · R43 · FY2022 · DK
A novel, non-antibiotic, microbiome-directed agent to prevent post-surgical infection
$299,066John C. Alverdy · Covira Surgical · R42 · FY2023 · AI
Chemical biology of type IV secretion systems
$299,064Carrie Shaffer · University Of Kentucky · P20 · FY2022 · GM
Early host microbial interactions in S. aureus pneumonia
$299,007Craig E. Rubens · University Of Washington · P50 · FY2007 · HL
Salmonella Antimicrobial Peptide Resistance
$299,000Ohio State University · R01 · FY2004 · AI
Salmonella Antimicrobial Peptide Resistance
$299,000Ohio State University · R01 · FY2005 · AI
Isolating novel actinomycetes for antibiotic discovery
$299,000Losee Lucy Ling · Novobiotic Pharmaceuticals, Llc · R43 · FY2008 · AI
2-adamantanamine Based Therapeutic for Recurrent Oropharyngeal Candidiasis
$298,990Thomas A Dahl · Arietis · R43 · FY2010 · DE
Molecular analysis of accurate ribosomal translocation
$298,984Kurt L Fredrick · Ohio State University · R01 · FY2019 · GM
Augmenting Innate Immunity to Protect the Oral Mucosa
$298,980Mark C Herzberg · University Of Minnesota · R01 · FY2012 · DE
Defensins in Innate Immunity to Viruses
$298,862Jason G Smith · University Of Washington · R56 · FY2012 · AI
Development of nitroreductase-activated inhibitors to treat mycobacterial infections
$298,829John James Vrbanac · Tarn Biosciences, Inc. · R41 · FY2025 · AI
Animal Model Core
$298,728Gerard J Nau · Miriam Hospital · P20 · FY2018 · GM
Project 1: Elucidating the Mechanisms of S. aureus Motility in Bone and Developing Interventions
$298,698Hani A Awad · University Of Rochester · P50 · FY2017 · AR
Antimicrobial peptides to combat MDR ESKAPE pathogens
$298,691Paul Guyre · Celdara Medical, Llc · R43 · FY2019 · AI
Enzyme therapeutics for biofilm prevention and disruption
$298,682Patricia Lynne Howell · Hospital For Sick Chldrn (Toronto) · R33 · FY2018 · AI
Bioorganic Approaches Toward Novel Antimicrobial Agents Against Gram-Negative Bacteria
$298,678Steven D. Townsend · Vanderbilt University · R35 · FY2019 · GM